Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × PT-100 dipeptide × Clear all
NCT04123574 2022-02-24

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

BioXcel Therapeutics Inc

Phase EARLY_PHASE1 Withdrawn
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00116389 2007-06-08

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Point Therapeutics

Phase 2 Terminated
60 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡